{"id":18494,"date":"2025-01-22T11:36:05","date_gmt":"2025-01-22T11:36:05","guid":{"rendered":"https:\/\/www.drfz.de\/?post_type=project&p=18494"},"modified":"2025-06-30T15:01:44","modified_gmt":"2025-06-30T15:01:44","slug":"jumbo-register-langzeitbeobachtung-fur-junge-erwachsene-mit-jia","status":"publish","type":"project","link":"https:\/\/www.drfz.de\/en\/forschungsprojekte\/jumbo-register-langzeitbeobachtung-fur-junge-erwachsene-mit-jia\/","title":{"rendered":"JuMBO (Juvenile arthritis MTX\/Biologics long-term Observation)"},"content":{"rendered":"\n
<\/div>\n\n\n\n\n\n\n\n
\n\n
\n

JuMBO\u2013 More than 2,100 young adults are being accompanied on their journey.<\/h3>\n \n \n
\n\n
\n \"\" <\/div>\n \n
\n \n

Who takes part in JuMBO?<\/h4>\n \n
\n

The average participant in the JuMBO study is 23 years old, and about two-thirds are female. The majority have polyarthritis, while one-third have spondyloarthritis. Many are still in school or vocational training, while more than a quarter are already employed.<\/p>\n <\/div>\n \n

\n Informationen f\u00fcr Studienteilnehmer:innen<\/span><\/a> <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n <\/section>\n\n\n\n\n

<\/p>\n\n\n\n

Selected Findings<\/h2>\n\n\n\n
\n\n
\n

Improved Disease Control and Higher Quality of Life<\/h2>\n \n
Due to the earlier and more widespread use of modern antirheumatic therapies, juvenile idiopathic arthritis (JIA) has become more manageable than ever before. Over the past 15 years, the proportion of patients with inactive disease in adulthood has doubled. Among the current JuMBO study participants, the disease is inactive or shows minimal activity in nearly 90% of cases.\r\nNevertheless, pharmacological treatment remains necessary for many individuals. Our data indicate that following the discontinuation of methotrexate (MTX), approximately 50% of patients experienced a disease relapse. This rate increases to 75% among those who discontinued biologic therapies. Consequently, any adjustment or tapering of treatment should always be conducted in close consultation with the treating physician (references).\r\nEncouragingly, if disease activity recurs and DMARD therapy is reinitiated, the treatment response is generally favorable: approximately 70% of patients regain inactive disease status within one year.\r\n\r\n<\/div>\n \n
\n\n \n
\n \n \n \n
\n Articel<\/span><\/a> <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n <\/section>\n\n\n\n\n
\n
\n
\n

Timing of Therapy Initiation as a Key Determinant of Treatment Outcomes<\/h2>\n
\n Articel<\/span><\/a> <\/div>\n <\/div>\n \n
Findings from the JuMBO study underscore the critical importance of timely therapy initiation for successful treatment outcomes. The data indicate that the earlier an effective therapy is introduced, the greater the probability of achieving drug-free remission in adulthood.<\/div>\n \n
\n \n \n

\n \n 50<\/span>\n\n %<\/span>\n <\/h3>\n \n
\n

Thanks to improved therapies, 50% of patients achieve inactive disease in adulthood. <\/p>\n <\/div>\n <\/div>\n\n \n \n

\n \n 90<\/span>\n\n %<\/span>\n <\/h3>\n \n
\n

Nearly 90% reach either inactive or minimally active disease status.<\/p>\n <\/div>\n <\/div>\n\n \n \n

\n \n 1<\/span>\n\n %<\/span>\n <\/h3>\n \n
\n

Only 1% of patients require joint replacement in early adulthood\u2014a figure that has significantly declined since 2007.<\/p>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n

\n